Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
This article proposes a mathematical modeling of longevity and an analysis of longevity risk in the field of demographics and life insurance.
SCOR's first quarter of 2012 results.
SCOR Global Life's Embedded Value results of 2011.
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
SCOR records net income of EUR 104 million in the 1st quarter 2012, confirming the dynamism of its franchise. SCOR Global Life Embedded Value grows by 50% to EUR 3.3 billion.
SCOR records net income of EUR 104 million in the 1st quarter 2012, confirming the dynamism of its franchise. SCOR Global Life Embedded Value grows by 50% to EUR 3.3 billion.
A.M. Best has upgraded the Issuer Credit Ratings (ICR) of SCOR SE and its main subsidiaries from “a” to “a+”. They have also affirmed the Financial Strength Ratings of “A” (Excellent).
The introduction of the new European supervisory System, Solvency II, is around the corner, even though now with a modified timetable compared to the initial planning.